Bally’s Corporation (NYSE: BALY) eyes evoke plc (LSE: EVOK): why a William Hill deal would reshape UK gambling
Read More Pharma Industry News NLS Pharmaceutics and Kadimastem merger gains BIRD Foundation boost for breakthrough Type 1 diabetes therapy Discover how NLS Pharmaceutics and Kadimastem’s merger, backed by renewed BIRD Foundation funding, positions NewCelX to challenge global leaders in diabetes cell therapy. bySoujanya RaviOctober 29, 2025